Laurus Labs Q1 Review - Formulation, Synthesis Outshines; API Underperforms: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Laurus Labs Ltd.'s Q1 FY22 earnings missed our expectations. The robust performances in the finished dosage formulations and synthesis segments were more than offset by a muted show in the active pharma ingredients segment.
That said, in addition to having an established business in the anti-retroviral segment, Laurus Labs is on track to build new levers for future growth in contract development and manufacturing operations and non-ARV API/formulation.
We tweak our FY22E/FY23E earnings per share estimate, factoring in-
Moderation in the API business,
Strong traction in synthesis and FDF, and
Enhanced capacity in the bio business.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.